Coagulation Factor DeficiencycoagdefNCT03273998
Cross-sectional Study on Prevalence of Coagulation Factors Deficiency in Assiut University Children Hospital
An observational study of Coagulation Factor Deficiency, run by Assiut University.
Trial summary
Blood coagulation is a complex mechanism that is required for the rapid establishment of a stable fibrin clot. A series of interdependent enzyme-mediated reactions translate the molecular signals that initiate blood coagulation into the formation of the fibrin clot. Read more about this study
- Who is it for?
- Ages Up to 18 years
- Conditions the study is for
- Coagulation Factor Deficiency
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- 1 Apr 2018to 1 Apr 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: children with coagulation factors deficiency in Assiut University Children Hospital
Who may be able to join
- All patients with congenital bleeding disorders secondary to coagulation factor deficiency and attending in Assiut University Children Hospital will be included in the study
Who cannot join
- Patients with:
- Acquired bleeding disorders Thrombasthenia thrombocytopenia
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Cross-sectional Study on Prevalence of Coagulation Factors Deficiency in Children Attending Assiut University Children Hospital ( a One Year Study)
Blood coagulation is a complex mechanism that is required for the rapid establishment of a stable fibrin clot. A series of interdependent enzyme-mediated reactions translate the molecular signals that initiate blood coagulation into the formation of the fibrin clot. Congenital coagulopathies result when there is a deficiency of protein co factors and enzymes implicated in blood coagulation
Read the detailed description
The most frequent inherited coagulation disorders are haemophilia A and B, due to the deficiency of factor VIII and IX. Haemophilia A and B are clinically indistinguishable from each other and occur in mild, moderate and severe forms (with plasma factor levels of 6-30%, 2-5% and 1% or less respectively). Inherited as X-linked traits, haemophilia A and B are prevalent in the general population of approximately 1 in 10 000 and 1 in 50 000, with no significant racial difference. Other deficiencies of coagulation factors that cause a bleeding disorder, such as afibrinogenaemia, hypoprothrombinaemia, deficiencies of factors V and combined factor V and VIII, VII, X, XI and XIII are inherited as autosomal recessive traits and are generally much rarer than the haemophilias, wich are prevalent in the general population varying between 1 in 500 000 and 1 in 2 000 000. As a consequence of the rarity of these deficiencies, which are expressed clinically only in homozygotes or compound heterozygotes, the type and severity of symptoms, the underlying molecular defects and the actual management of bleeding episodes are not well established as for haemophilia A and B.
Inherited deficiencies are described for all of the known coagulation factors. In addition, there are people with an abnormal bleeding tendency for whom no cause has yet been identified. The concept of overall hemostatic balance is increasingly recognized, that it is not solely the level of a single factor that matters, but the overall control of hemostasis that may determine the bleeding risk. This may explain why the bleeding risk cannot be predicted from a single factor level alone as in, for example, factor VII or factor XI deficiency in particular. The rare factor deficiencies have several common properties: they are inherited in an autosomal manner, although bleeding symptoms have been described in heterozygous partially deficient individuals. These rare deficiencies are more common in populations and countries where cousin marriages are frequent and therefore there is considerable geographic variation in the incidence, in contrast to hemophilia and von Willebrand disease types I or II which occur with the same incidence in different countries.
Clinical manifestations:
In their most severe form, the deficiencies present with serious hemorrhage in the neonatal period; intracranial hemorrhage is a significant presentation of severe deficiency of FXIII, factor VII, factor X or fibrinogen (afibrinogenaemia). Bleeding from the umbilical stump can occur with any of these disorders as it can with severe hemophilia. It is important for caregivers to be aware that any unusual bleeding manifestation must prompt appropriate investigation so that diagnosis is not delayed, and appropriate replacement therapy is given as soon as possible. A history of consanguinity of the parents and their ethnic origin are relevant.
Diagnosis should be straightforward but there are pitfalls in testing. Difficult venepunctures in infants in an emergency may give erroneous results due to tissue factor contamination. Coagulation samples do not travel well, so if plasma samples are sent to another laboratory they must be properly transported, generally frozen and sent on dry ice. It may be helpful to test both parents because, apart from the two truly recessive disorders detailed below, the parents will usually have evidence of partial deficiency. It is important for each laboratory to establish its own normal range, and to ensure that the possibility of genetic carriage of a disorder is fully discussed with parents irrespective of the blood results as the birth of more children with a serious bleeding disorder is a great emotional and social burden especially in countries and communities with poor health resources.
Fibrinogen deficiency
Fibrinogen deficiency is heterogeneous and two main phenotypes can be distinguished. In afibrinogenaemia, plasma and platelet levels of the protein are unmeasurable or very low when using assays that measure clottable and immunoreactive protein, whereas in dysfibrinogenaemia low clottable fibrinogen contrasts with normal or moderately reduced fibrinogen antigen.
Clinical manifestations:
Whereas most patients with dysfibrinogenaemia do not bleed at all, afibrinogenaemic patients have a bleeding tendency.
Among severe bleeding symptoms that are dangerous for life and for the musculoskeletal function, umbilical cord and joint bleeding is relatively frequent (in 75% and 50% of patients), whereas muscle hematomas and bleeding in the gastrointestinal tract and central nervous system are less common.
Milder symptoms such as epistaxis and menorrhagia are also frequent. Post-partum bleeding occurs when no prophylactic replacement therapy is given. Excessive blood loss and impaired wound healing in about one-third of the patients often accompany circumcision and other surgical maneuvers. There is no increased prevalence of recurrent miscarriages. Central nervous system bleeding is rare.
Factor V deficiency Congenital factor V deficiency (also known as labile factor or proaccelerin) is a rather uncommon [1:1000,000] inherited coagulopathy (autosomal recessive inheritance).
Affected patients become symptomatic in early childhood with spontaneous or post- traumatic bleeding complications
Factor VII deficiency
Factor VII deficiency is the most common autosomal recessive coagulation disorder (1 per 500 000 population). Factor VII circulates in plasma at a concentration of approximately 0.5 μg/mL (10 mmol/L). Plasma levels of factor VII coagulant activity (FVII:C) and FVII antigen (FVII: Ag) are influenced by a number of genetic and environmental factors (sex, age, cholesterol and triglyceride levels). The majority of patients have concomitantly low levels of factor VII functional activity and antigen, but several cases are characterized by normal or low borderline levels of factor VII antigen, contrasting with lower levels of functional activity. Most gene knockout mice made experimentally deficient in factor VII develop normally but some suffer fatal perinatal bleeding.
Clinical manifestations:
The severity of symptoms of factor VII deficiency is variable and generally reported to be poorly correlated with plasma levels. Some patients do not bleed at all after major challenges of haemostasis, and even cases of thrombosis have been described. life- or limb-endangering bleeding manifestations are relatively rare, the most frequent symptoms being epistaxis and menorrhagia. However, the prevalence of haemarthroses and soft-tissue bleeding was less than that found in other large series. The risk of central nervous system bleeding in infants with severe factor VII deficiency is high in some series.
Factor VIII \& factor IX deficiency:
The hemophilias are X-linked congenital bleeding disorders, and the two major categories are hemophilia A (factor VIII deficiency, seen in 1 in 5,000 male births) and hemophilia B (factor IX deficiency, seen 1 in 30,000 male births) Prophylaxis for children with severe hemophilia consists of infusion of a factor concentrate two or three times a week in order to keep blood levels of factor VIII or IX high enough to prevent bleeding. On-demand therapy involves infusion of a factor concentrate immediately after bleeding starts in an effort to prevent joint or muscle damage
Factor XI deficiency Factor XI deficiency is characterized by a decrease of the functional activity of this plasma protein, usually accompanied by correspondingly low levels of factor XI antigen. Most of cases reported in the literature are of Ashkenazi Jewish origin, the frequency of heterozygosity for factor XI deficiency being as high as 8% in this population. In knockout mice, the loss of the gene coding for this factor is compatible with life, with no tendency for spontaneous bleeding.
Clinical manifestations:
The relationship between the residual factor XI levels in plasma and the bleeding tendency is not as clear-cut as for other coagulation factor deficiencies. Usually, patients with severe factor XI deficiency (1% or less) are mildly affected and have bleeding symptoms only after trauma or surgery. Surprisingly patients with low but detectable levels of factor XI are also mild bleeders, severe or moderate deficiency (factor XI < 1-5%) and in patients with mild deficiency (6-30%). All patients were mild bleeders, but those symptoms that define the severity of the bleeding tendency, such as muscle hematomas and hemarthroses, showed a similar frequency in the two groups of deficient patients (approximately 25%). The most frequent symptoms were oral and post-operative bleeding, which occurred in more than 50% of patients.
Differential diagnosis :
Causes of congenital bleeding disorders
The most common include:
Von Willebrand Disease Hemophilia A (Factor Viii Deficiency) Hemophilia B(Factor Ix Deficiency)
Less Common :
Factor 1(Fibrinogen Deficiency) Factor II (Prothrombin Deficiency or Dysfunction) Factor V Deficiency Factor VII Deficiency Factor X Deficiency Factor XI Deficiency Factor XIII Deficiency Platelet Disorders Congenital Aplastic Anemia
- Conditions
- Coagulation Factor Deficiency
- Keywords
- coagulation, bleeding
- Medical subject headings
- Thrombosis, Hemorrhage
What is being measured
The primary outcome is the main question the study is designed to answer.
prevalence of children with coagulation factors deficiency in Assiut University Children Hospital measured by coagulation factor deficiency checklist
data collected in sheet measuring type and level of deficient factor and measuring clotting tests(e.g. pt ,aptt)
Measured: 1year
Secondary outcomes (2)
evaluation of inheritance of coagulation fa tors deficiency through the checklist measuring other affected family members
number of family members having coag factors deficiency , their age ,sex
Measured: 1year
evaluation of infectious disease by measuring hepatitis c virus and human immunodeficiency virus
hepatitis c virus and human immunodeficiency virus testing
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Sep 2017
- Study start1 Apr 2018 (estimated)
- Primary completion1 Apr 2019 (estimated)
- Study completion1 Apr 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Coagulation Factor DeficiencyStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, YHAlattar, Assiut University
- Investigators
- yomna alattar, resident, Principal investigator, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03273998
- Sponsor's protocol ID
- Coag Def
- Acronym
- coagdef
- Status last verified
- Sep 2017
- First submitted
- 29 Aug 2017
- Last updated
- 12 Sep 2017
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood. 2004 Sep 1;104(5):1243-52. doi: 10.1182/blood-2004-02-0595. Epub 2004 May 11.
PubMed 15138162Bolton-Maggs PH. The rare inherited coagulation disorders. Pediatr Blood Cancer. 2013;60 Suppl 1:S37-40. doi: 10.1002/pbc.24336. Epub 2012 Oct 25.
PubMed 23109366Peyvandi F, Mannucci PM. Rare coagulation disorders. Thromb Haemost. 1999 Oct;82(4):1207-14.
PubMed 10544899Ehrenforth S, Klarmann D, Zabel B, Scharrer I, Kreuz W. Severe factor V deficiency presenting as subdural haematoma in the newborn. Eur J Pediatr. 1998 Dec;157(12):1032. doi: 10.1007/s004310050993. No abstract available.
PubMed 9877047Kulkarni R, Soucie JM. Pediatric hemophilia: a review. Semin Thromb Hemost. 2011 Oct;37(7):737-44. doi: 10.1055/s-0031-1297164. Epub 2011 Dec 20.
PubMed 22187396von der Lippe C, Frich JC, Harris A, Solbraekke KN. Treatment of hemophilia: A qualitative study of mothers' perspectives. Pediatr Blood Cancer. 2017 Jan;64(1):121-127. doi: 10.1002/pbc.26167. Epub 2016 Jul 29.
PubMed 27472376KENDALL AG, LOWENSTEIN L. Alterations in blood coagulation and hemostasis during extracorporeal circulation. II. Can Med Assoc J. 1962 Oct 20;87(16):859-64. No abstract available.
PubMed 14031889
Study at a glance
From the registry record, last updated by the sponsor on 12 Sep 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cross-sectional Study on Prevalence of Coagulation Factors Deficiency in Children Attending Assiut University Children Hospital ( a One Year Study)
- ClinicalTrials.gov ID
- NCT03273998
- Acronym / sponsor ID
- coagdef / Coag Def
- Conditions
- Coagulation Factor Deficiency
- Keywords
- coagulation, bleeding
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Apr 2018 (estimated)
- Primary completion
- 1 Apr 2019 (estimated)
- Study completion
- 1 Apr 2019 (estimated)
- First posted
- 6 Sep 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Blood coagulation is a complex mechanism that is required for the rapid establishment of a stable fibrin clot. A series of interdependent enzyme-mediated reactions translate the molecular signals that initiate blood coagulation into the formation of the fibrin clot. Congenital coagulopathies result when there is a deficiency of protein co factors and enzymes implicated in blood coagulation
Detailed description
The most frequent inherited coagulation disorders are haemophilia A and B, due to the deficiency of factor VIII and IX. Haemophilia A and B are clinically indistinguishable from each other and occur in mild, moderate and severe forms (with plasma factor levels of 6-30%, 2-5% and 1% or less respectively). Inherited as X-linked traits, haemophilia A and B are prevalent in the general population of approximately 1 in 10 000 and 1 in 50 000, with no significant racial difference. Other deficiencies of coagulation factors that cause a bleeding disorder, such as afibrinogenaemia, hypoprothrombinaemia, deficiencies of factors V and combined factor V and VIII, VII, X, XI and XIII are inherited as autosomal recessive traits and are generally much rarer than the haemophilias, wich are prevalent in the general population varying between 1 in 500 000 and 1 in 2 000 000. As a consequence of the rarity of these deficiencies, which are expressed clinically only in homozygotes or compound heterozygotes, the type and severity of symptoms, the underlying molecular defects and the actual management of bleeding episodes are not well established as for haemophilia A and B.
Inherited deficiencies are described for all of the known coagulation factors. In addition, there are people with an abnormal bleeding tendency for whom no cause has yet been identified. The concept of overall hemostatic balance is increasingly recognized, that it is not solely the level of a single factor that matters, but the overall control of hemostasis that may determine the bleeding risk. This may explain why the bleeding risk cannot be predicted from a single factor level alone as in, for example, factor VII or factor XI deficiency in particular. The rare factor deficiencies have several common properties: they are inherited in an autosomal manner, although bleeding symptoms have been described in heterozygous partially deficient individuals. These rare deficiencies are more common in populations and countries where cousin marriages are frequent and therefore there is considerable geographic variation in the incidence, in contrast to hemophilia and von Willebrand disease types I or II which occur with the same incidence in different countries.
Clinical manifestations:
In their most severe form, the deficiencies present with serious hemorrhage in the neonatal period; intracranial hemorrhage is a significant presentation of severe deficiency of FXIII, factor VII, factor X or fibrinogen (afibrinogenaemia). Bleeding from the umbilical stump can occur with any of these disorders as it can with severe hemophilia. It is important for caregivers to be aware that any unusual bleeding manifestation must prompt appropriate investigation so that diagnosis is not delayed, and appropriate replacement therapy is given as soon as possible. A history of consanguinity of the parents and their ethnic origin are relevant.
Diagnosis should be straightforward but there are pitfalls in testing. Difficult venepunctures in infants in an emergency may give erroneous results due to tissue factor contamination. Coagulation samples do not travel well, so if plasma samples are sent to another laboratory they must be properly transported, generally frozen and sent on dry ice. It may be helpful to test both parents because, apart from the two truly recessive disorders detailed below, the parents will usually have evidence of partial deficiency. It is important for each laboratory to establish its own normal range, and to ensure that the possibility of genetic carriage of a disorder is fully discussed with parents irrespective of the blood results as the birth of more children with a serious bleeding disorder is a great emotional and social burden especially in countries and communities with poor health resources.
Fibrinogen deficiency
Fibrinogen deficiency is heterogeneous and two main phenotypes can be distinguished. In afibrinogenaemia, plasma and platelet levels of the protein are unmeasurable or very low when using assays that measure clottable and immunoreactive protein, whereas in dysfibrinogenaemia low clottable fibrinogen contrasts with normal or moderately reduced fibrinogen antigen.
Clinical manifestations:
Whereas most patients with dysfibrinogenaemia do not bleed at all, afibrinogenaemic patients have a bleeding tendency.
Among severe bleeding symptoms that are dangerous for life and for the musculoskeletal function, umbilical cord and joint bleeding is relatively frequent (in 75% and 50% of patients), whereas muscle hematomas and bleeding in the gastrointestinal tract and central nervous system are less common.
Milder symptoms such as epistaxis and menorrhagia are also frequent. Post-partum bleeding occurs when no prophylactic replacement therapy is given. Excessive blood loss and impaired wound healing in about one-third of the patients often accompany circumcision and other surgical maneuvers. There is no increased prevalence of recurrent miscarriages. Central nervous system bleeding is rare.
Factor V deficiency Congenital factor V deficiency (also known as labile factor or proaccelerin) is a rather uncommon [1:1000,000] inherited coagulopathy (autosomal recessive inheritance).
Affected patients become symptomatic in early childhood with spontaneous or post- traumatic bleeding complications
Factor VII deficiency
Factor VII deficiency is the most common autosomal recessive coagulation disorder (1 per 500 000 population). Factor VII circulates in plasma at a concentration of approximately 0.5 μg/mL (10 mmol/L). Plasma levels of factor VII coagulant activity (FVII:C) and FVII antigen (FVII: Ag) are influenced by a number of genetic and environmental factors (sex, age, cholesterol and triglyceride levels). The majority of patients have concomitantly low levels of factor VII functional activity and antigen, but several cases are characterized by normal or low borderline levels of factor VII antigen, contrasting with lower levels of functional activity. Most gene knockout mice made experimentally deficient in factor VII develop normally but some suffer fatal perinatal bleeding.
Clinical manifestations:
The severity of symptoms of factor VII deficiency is variable and generally reported to be poorly correlated with plasma levels. Some patients do not bleed at all after major challenges of haemostasis, and even cases of thrombosis have been described. life- or limb-endangering bleeding manifestations are relatively rare, the most frequent symptoms being epistaxis and menorrhagia. However, the prevalence of haemarthroses and soft-tissue bleeding was less than that found in other large series. The risk of central nervous system bleeding in infants with severe factor VII deficiency is high in some series.
Factor VIII \& factor IX deficiency:
The hemophilias are X-linked congenital bleeding disorders, and the two major categories are hemophilia A (factor VIII deficiency, seen in 1 in 5,000 male births) and hemophilia B (factor IX deficiency, seen 1 in 30,000 male births) Prophylaxis for children with severe hemophilia consists of infusion of a factor concentrate two or three times a week in order to keep blood levels of factor VIII or IX high enough to prevent bleeding. On-demand therapy involves infusion of a factor concentrate immediately after bleeding starts in an effort to prevent joint or muscle damage
Factor XI deficiency Factor XI deficiency is characterized by a decrease of the functional activity of this plasma protein, usually accompanied by correspondingly low levels of factor XI antigen. Most of cases reported in the literature are of Ashkenazi Jewish origin, the frequency of heterozygosity for factor XI deficiency being as high as 8% in this population. In knockout mice, the loss of the gene coding for this factor is compatible with life, with no tendency for spontaneous bleeding.
Clinical manifestations:
The relationship between the residual factor XI levels in plasma and the bleeding tendency is not as clear-cut as for other coagulation factor deficiencies. Usually, patients with severe factor XI deficiency (1% or less) are mildly affected and have bleeding symptoms only after trauma or surgery. Surprisingly patients with low but detectable levels of factor XI are also mild bleeders, severe or moderate deficiency (factor XI < 1-5%) and in patients with mild deficiency (6-30%). All patients were mild bleeders, but those symptoms that define the severity of the bleeding tendency, such as muscle hematomas and hemarthroses, showed a similar frequency in the two groups of deficient patients (approximately 25%). The most frequent symptoms were oral and post-operative bleeding, which occurred in more than 50% of patients.
Differential diagnosis :
Causes of congenital bleeding disorders
The most common include:
Von Willebrand Disease Hemophilia A (Factor Viii Deficiency) Hemophilia B(Factor Ix Deficiency)
Less Common :
Factor 1(Fibrinogen Deficiency) Factor II (Prothrombin Deficiency or Dysfunction) Factor V Deficiency Factor VII Deficiency Factor X Deficiency Factor XI Deficiency Factor XIII Deficiency Platelet Disorders Congenital Aplastic Anemia
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- Up to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- children with coagulation factors deficiency in Assiut University Children Hospital
Key inclusion criteria (1 listed)
- All patients with congenital bleeding disorders secondary to coagulation factor deficiency and attending in Assiut University Children Hospital will be included in the study
Key exclusion criteria (2 listed)
- Patients with:
- Acquired bleeding disorders Thrombasthenia thrombocytopenia
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
prevalence of children with coagulation factors deficiency in Assiut University Children Hospital measured by coagulation factor deficiency checklist
Time frame: 1year
data collected in sheet measuring type and level of deficient factor and measuring clotting tests(e.g. pt ,aptt)
2 secondary outcomes
evaluation of inheritance of coagulation fa tors deficiency through the checklist measuring other affected family members
Time frame: 1year
evaluation of infectious disease by measuring hepatitis c virus and human immunodeficiency virus
Time frame: one year
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Sep 2017.
- Results publication: PubMed 15138162Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood. 2004 Sep 1;104(5):1243-52. doi: 10.1182/blood-2004-02-0595. Epub 2004 May 11.
- Results publication: PubMed 23109366Bolton-Maggs PH. The rare inherited coagulation disorders. Pediatr Blood Cancer. 2013;60 Suppl 1:S37-40. doi: 10.1002/pbc.24336. Epub 2012 Oct 25.
- Results publication: PubMed 10544899Peyvandi F, Mannucci PM. Rare coagulation disorders. Thromb Haemost. 1999 Oct;82(4):1207-14.
- Results publication: PubMed 9877047Ehrenforth S, Klarmann D, Zabel B, Scharrer I, Kreuz W. Severe factor V deficiency presenting as subdural haematoma in the newborn. Eur J Pediatr. 1998 Dec;157(12):1032. doi: 10.1007/s004310050993. No abstract available.
- Results publication: PubMed 22187396Kulkarni R, Soucie JM. Pediatric hemophilia: a review. Semin Thromb Hemost. 2011 Oct;37(7):737-44. doi: 10.1055/s-0031-1297164. Epub 2011 Dec 20.
- Results publication: PubMed 27472376von der Lippe C, Frich JC, Harris A, Solbraekke KN. Treatment of hemophilia: A qualitative study of mothers' perspectives. Pediatr Blood Cancer. 2017 Jan;64(1):121-127. doi: 10.1002/pbc.26167. Epub 2016 Jul 29.
- Results publication: PubMed 14031889KENDALL AG, LOWENSTEIN L. Alterations in blood coagulation and hemostasis during extracorporeal circulation. II. Can Med Assoc J. 1962 Oct 20;87(16):859-64. No abstract available.
- Individual participant dataSharing planned: No
Related trials for Coagulation Factor Deficiency
RecruitingObservational study
A Database For The Collection Of Clinical, Laboratory, And Treatment Data From Patients With Factor X Deficiency To Define The Natural History Of The Disease And Improve Patient Management
Factor X Deficiency
RecruitingPhase 4
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
Factor VIII Deficiency
RecruitingPhase 3
Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)
Complex Cardiovascular Surgery With Cardiopulmonary Bypass
RecruitingPhase 3
Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery
Acquired Fibrinogen Deficiency
RecruitingObservational study
Point of Care Fibrinogen Measurement in Trauma Patients in the Emergency Department
Trauma Induced Coagulopathy, Trauma Coagulopathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
yomna alattar, resident principal investigator
Assiut University
Questions about this trial
What is this clinical trial studying?
An observational study of Coagulation Factor Deficiency, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 12 Sep 2017. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Khalid Ibrahim El-Sayeh, Professor (01005484357, elsayh23@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
prevalence of children with coagulation factors deficiency in Assiut University Children Hospital measured by coagulation factor deficiency checklist (time frame: 1year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03273998, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Sep 2017.